CRO. Retain a chief restructuring officer of the Borrower and the other Debtors (“CRO”), the retention of which shall be approved by the Bankruptcy Court and the engagement and retention of which shall be acceptable to the Postpetition Lender. Xxx Xxxxxxx of AlixPartners shall be deemed acceptable by the Postpetition Lender as a CRO.
CRO. The term “
CRO. Společnost smluvně zavázala CRO jakožto nezávislého dodavatele smluvního plnění k provedení určitých služeb smluvní výzkumné organizace v souvislosti s tímto Klinickým hodnocením, a to včetně vyjednání smluv o klinickém hodnocení s jednotlivými xxxxx výkonu klinického hodnocení, resp. centry, jménem a ve prospěch Společnosti. Instituce souhlasí, že zajistí, že Hlavní zkoušející a personál zapojený do provádění Klinického hodnocení poskytnou plnou součinnost CRO, a to z pozice smluvní výzkumné organizace jednající jménem Společnosti ve vztahu ke Klinickému hodnocení (a případně zástupci či zmocněnci CRO, dle konkrétních podmínek), stejně jako jsou Instituce a Hlavní zkoušející povinni spolupracovat a poskytovat součinnost Společnosti v téže souvislosti.
CRO. Sponsor has retained CRO as in independent contractor to perform certain contract research organization services in connection with the Clinical Trial, including negotiation of Clinical Trial Agreements with Clinical Trial sites on behalf of Sponsor. The Provider agrees that it shall ensure the Principal Investigator and all Cooperating Personnel shall, fully cooperate with CRO in its capacity as Sponsor’s contract research organization for the Clinical Trial (and CRO’s designee, if applicable), in the same way that Provider and Principal Investigator are obliged to cooperate with Sponsor related thereto.
CRO. Company has retained CRO as in independent contractor to perform certain contract research organization services in connection with the Clinical Trial, including negotiation of Clinical Trial Agreements with Clinical Trial sites on behalf of Company. The Institution agrees that it shall ensure the Principal Investigator and all Clinical Trial staff shall, fully cooperate with CRO in its capacity as Company’s contract research organization for the Clinical Trial (and CRO’s designee, if applicable), in the same way that Institution and Principal Investigator are obliged to cooperate with Company related thereto.
CRO. Company has retained CRO as in independent contractor to perform certain contract research organization services in connection with the Clinical Trial, including 3, předpisů a nebudou-li získány souhlasy požadované za účelem provedení Klinického hodnocení.
1.3 Písemný informovaný souhlas. Hlavní zkoušející je zodpovědný za opatření řádně podepsaného písemného souhlasu od každého Subjektu hodnocení účastnícího se Klinického hodnocení (každý jednotlivě xxxx xxx “Subjekt hodnocení”), a to v podobě schválené EK / SÚKL a Společností v souladu s Příslušnými právními předpisy. Instituce je povinna evidovat takový dokument v souladu s vnitřními pravidly Instituce, přičemž poskytne jeho kopii Společnosti na její žádost. Žádný Subjekt hodnocení nebude zařazen do Klinického hodnocení, nebyl-li předtím opatřen jeho písemný infomovaný souhlas.
CRO. The Borrowers hereby agree that the CRO shall have, and shall be delegated, the following rights, power and authority, in his capacity as a director and with appropriate day-to-day decision authority to interact with key constituents, the Administrative Agent and the Lenders, and to instruct employees to support the CRO’s efforts, and to take such action on the Loan Parties’ behalf as described in this Credit Agreement or elsewhere and as follows:
(a) subject to Section 7.05 of this Credit Agreement, the right to veto any Disposition of assets by the Loan Parties, which shall not be completed by the Loan Parties without the approval of the CRO;
(b) the right to veto all new material agreements and modifications to any Material Contract, which shall not be entered into by the Loan Parties without the approval of the CRO;
(c) the right to veto any transactions by and among the Loan Parties with any terminal servicing agreement counterparty or shared facilities counterparty, which shall not be entered into by the Loan Parties without the approval of the CRO;
(d) the right to veto any transactions and agreements with USDG and its affiliates, which shall not be entered into by the Loan Parties without the approval of the CRO;
(e) sole authority on behalf of the Loan Parties with respect to any Restructuring Transaction; provided that the Conflicts Committee shall have sole power and authority with respect to the institution or defense of, or consent (whether express or by failure to act) to, any proceeding, case or other action under any Debtor Relief Law or with respect to any exercise of rights under Article 9 of the UCC or under any deed of trust, mortgage, or similar security agreement;.
(f) the right to make final approval and final disapproval decisions with respect to the Loan Parties’ proposed and/or actual budgets and disbursements for expenses incurred after the Amendment No. 5 Effective Date (including but not limited to Approved G&A Expenses, Corporate G&A Expenses, Administrative G&A Expenses, Facilities Operations Expenses, Public Company Costs); and
(g) the right to all necessary access, information, and support on a day-to-day basis to fulfill the CRO’s rights, power and authority with respect to the Loan Parties; include the right to direct employees in fulfillment of the CRO’s rights an authorities provided herein; and
(h) the right to meet and communicate with key constituents, including the Administrative Agent and the Lenders, which meeting...
CRO. On or prior to July 1, 2014 and at all times thereafter, engage Xxxxxxx X. Xxxxx (or another representative of the Financial Advisor selected by the Domestic Borrower and reasonably acceptable to the Required Lenders) as chief restructuring officer of the Domestic Borrower (“CRO”), on terms, conditions and scope of authority acceptable to the Administrative Agent and the Required Lenders.
CRO. (a) The Company shall provide the Holder and its agents and advisors with access to the chief restructuring officer (the “CRO”), and the CRO shall provide the Holder with a weekly telephonic update (provided that the Company shall only be required to provide one such update each week for all the “Noteholders” as defined in the Note Amendment Agreement at a time approved by the Required Holders) but only if the Holder has requested the same) as to the Company’s operations and restructuring progress. By requesting or participating in such updates, Holder shall be deemed to have acknowledged that such updates may disclose material non-public information about the Company and its Subsidiaries and agrees that it will keep all such information confidential in accordance with the non-disclosure agreement between the Holder and the Company and, if no such non-disclosure agreement exists, the Holder and the Company shall first enter into such a non-disclosure agreement in form and substance reasonably satisfactory to the Company and the Holder.
(b) The Company shall not terminate or replace Winston Mar as the CRO or reduce the authority of the CRO without the prior written consent of the Required Holders.”
(e) The following sub-sections of Section 3.1 of the Notes are hereby amended in full to read as follows:
(a) (i) the Company’s failure to pay to the Holder on the Maturity Date all amounts then due and owing under the Note, including the outstanding Principal, all accrued but unpaid Interest and any other amounts which are then due and owing in accordance herewith, or (ii) the Company’s or any Subsidiary’s failure to pay to the Holder, or its agent, any amount of Principal, Interest and any other amounts required to be paid hereunder or under any other Transaction Document as and when due hereunder or thereunder and such failure remains uncured for a period of five (5) days;”
